So investiert der LO Selection - NextGen BioTech Syst. Hdg EUR IA Fonds: The Sub-Fund invests primarily in equity securities or equity-related securities issued by companies worldwide (including Emerging Markets) exercising a prominent part of their business activities in the healthcare industry. The Investment Manager’s approach focuses on small and mid-cap biotechnology companies providing positive impact through disruptive, next generation innovations that can bring, among other things, better treatment solutions while lowering the financial burden for society.